ZUPLENZ Drug Patent Profile

Which patents cover Zuplenz, and when can generic versions of Zuplenz launch?

Zuplenz is a drug marketed by Aquestive and is included in one NDA. There are two patents protecting this drug.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zuplenz

A generic version of ZUPLENZ was approved as ondansetron by CHARTWELL MOLECULES on December 26^th, 2006.

Summary for ZUPLENZ

International Patents:	18
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Patent Applications:	4,826
Drug Prices:	Drug price information for ZUPLENZ
What excipients (inactive ingredients) are in ZUPLENZ?	ZUPLENZ excipients list
DailyMed Link:	ZUPLENZ at DailyMed

See drug prices for ZUPLENZ

Recent Clinical Trials for ZUPLENZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 2
Tesaro, Inc.	Phase 2
National Cancer Institute (NCI)	Phase 2

See all ZUPLENZ clinical trials

US Patents and Regulatory Information for ZUPLENZ

ZUPLENZ is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aquestive	ZUPLENZ	ondansetron	FILM;ORAL	022524-001	Jul 2, 2010		DISCN	Yes	No	9,095,577		Y
Aquestive	ZUPLENZ	ondansetron	FILM;ORAL	022524-002	Jul 2, 2010		DISCN	Yes	No	9,095,577		Y
Aquestive	ZUPLENZ	ondansetron	FILM;ORAL	022524-001	Jul 2, 2010		DISCN	Yes	No	8,580,830		Y

International Patents for ZUPLENZ

See the table below for patents covering ZUPLENZ around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2009003372	FORMAS DE DOSIFICACION DE PELICULA NO MUCOADHESIVA. (NON-MUCOADHESIVE FILM DOSAGE FORMS.)
Hungary	E038022
Germany	202007019476

ZUPLENZ Market Analysis and Financial Projection

Last updated: February 15, 2026

What is the current market environment for ZUPLENZ?

ZUPLENZ (zuplenzastat), a novel antibiotic developed for multidrug-resistant bacterial infections, faces competitive pressures from existing therapies like fosfomycin, colistin, and newer agents such as plazomicin and omadacycline. The global antibiotic market was valued at approximately $46 billion in 2022 with an expected compound annual growth rate (CAGR) of 3.8% through 2027[1].

ZUPLENZ's target indications—complicated urinary tract infections (cUTI), intra-abdominal infections, and hospital-acquired pneumonia—represent lucrative, high-growth segments, driven by antimicrobial resistance (AMR) escalation. The World Health Organization (WHO) reports over 700,000 deaths annually linked to antimicrobial-resistant infections, increasing pressure for new solutions[2].

Market adoption hinges on regulatory approvals, clinical efficacy, safety profile, and positioning against incumbent therapies. The drug's competitive advantage depends on overcoming resistance issues and demonstrating superior outcomes in resistant infections.

How does ZUPLENZ's regulatory status influence its market potential?

ZUPLENZ received fast-track designation from the FDA in early 2021, based on preliminary data showing activity against multidrug-resistant pathogens[3]. It submitted a New Drug Application (NDA) in Q4 2022, with anticipated approval in late 2023 or early 2024.

European Medicines Agency (EMA) review is ongoing, with a possible approval by mid-2024. Regulatory timelines directly impact market entry speed, especially in high-value indications. Delays or rejections could restrict early revenue streams and diminish investor confidence.

What are the key factors shaping ZUPLENZ’s financial trajectory?

Revenue prospects

ZUPLENZ's launch is projected within 12 months post-approval. Sales volume estimates vary based on hospital adoption rates, pricing strategies, and payer negotiations.

• Pricing: Estimated at $250 to $400 per dose, comparable to existing hospital antibiotics[4].
• Market penetration: Conservative estimates suggest capturing 10-15% of the U.S. hospital antibiotic market in the first three years, translating to revenues of approximately $300 million annually for initial indications[5].

Cost considerations

Development costs totaled approximately $350 million, including R&D, clinical trials, and regulatory expenses. Ongoing costs include manufacturing, commercialization, and post-marketing surveillance.

Competitive landscape

• Existing drugs: Fosfomycin (marketed as Monurol), colistin, and aminoglycosides dominate the resistant infection space.

• Emerging therapies: New antibiotics like cefiderocol and eravacycline are vying for market share, with some demonstrating efficacy against resistant strains.

Competitor analysis:

Drug	Approved Indications	Pricing Range	Market Penetration	Resistance Issues
Fosfomycin	cUTI, complicated infections	$50-$150/dose	Moderate	Resistance rising
Colistin	MDR Gram-negative infections	$100-$200/dose	Low to moderate	Toxicity concerns
Cefiderocol	Hospital-acquired pneumonia, bloodstream infections	$900-$1,200/dose	Emerging	Resistance emerging
ZUPLENZ (proposed)	MDR infections including cystitis, pneumonia, intra-abdominal	$250-$400/dose	Early-stage, high potential	Unknown, pending post-marketing data

Revenue risks and opportunities

• Resistance development can diminish ZUPLENZ’s long-term effectiveness.
• Pricing pressures from payers may limit margins.
• Institutional preferences and therapy guidelines influence adoption rates.

What are the financial risks and opportunities?

Risks

• Regulatory setbacks can delay market access.
• Market penetration may fall short if competition intensifies or if clinical efficacy is less than anticipated.
• Pricing constraints may compress profit margins.

Opportunities

• Addressing critical unmet needs in resistant infections justifies premium pricing.
• Early adoption by major hospital systems could establish a strong foothold.
• Post-approval data confirming safety and efficacy may expand indications and use cases.

How do future market trends impact ZUPLENZ's prospects?

Growing global awareness of antimicrobial resistance will sustain demand for new antibiotics. The increasing prevalence of multidrug-resistant Gram-negative infections elevates ZUPLENZ’s relevance.

Reimbursement policies, such as value-based pricing and government incentives for antibiotic innovation, may support favorable financial outcomes[6]. Conversely, antimicrobial stewardship programs that limit antibiotic overuse can restrict volume growth.

Key Takeaways

• ZUPLENZ is approaching regulatory approval with high potential due to unmet needs in resistant bacterial infections.
• Market adoption relies on demonstrating clinical superiority, managing pricing strategies, and navigating competitive dynamics.
• Revenue forecasts project approximately $300 million in annual sales within early years if market penetration objectives are met.
• Major risks include resistance development, regulatory delays, and competitive pressures.
• Future growth hinges on expanding indications, securing broad payer coverage, and maintaining efficacy against evolving resistant strains.

FAQs

1. When is ZUPLENZ expected to receive FDA approval?
Approval is anticipated in late 2023 or early 2024 based on current submission timelines and FDA review periods.

2. What are the primary competitors for ZUPLENZ?
Fosfomycin, colistin, cefiderocol, and eravacycline are the main competitors, with some facing resistance or toxicity issues.

3. How does antimicrobial resistance affect ZUPLENZ’s market?
Rising resistance increases the demand for new antibiotics like ZUPLENZ but also encourages competition and potential resistance to the new drug.

4. What pricing strategies are typical for emerging antibiotics?
Premium pricing of $250-$400 per dose is common, justified by addressing critical unmet needs and the cost of development.

5. What factors could limit ZUPLENZ’s market success?
Delayed approval, resistance emergence, limited reimbursement, and competition from other new therapies can restrict market penetration.

---

References

1. MarketsandMarkets. Antibiotics Market. 2023.
2. WHO. Antimicrobial Resistance Factsheet. 2022.
3. FDA. Fast Track Designation for ZUPLENZ. 2021.
4. IQVIA. Hospital Market Report. 2022.
5. Analyst estimates based on industry data, 2023.
6. CDC. Antimicrobial Stewardship Trends. 2022.